www.faf.cuni.cz|Students|Staff|E-mail

Home  >  Personal Profiles  >  Jirkovsky Eduard

Eduard Jirkovsky, PharmD., PhD.

Personal Profiles

Born: February 21, 1984, Tabor, Czech Republic.

https://orcid.org/0000-0003-4286-4811
Web of Science ResearcherID: A-7297-2017
Scopus ID: 36627424600

Current Position

  • Assistant professor at Dpt. Pharmacology and Toxicology

Education

  • 2015 – PharmD. (Fac. Pharmacy, Charles Univ.)
  • 2013 – PhD. in Medical Pharmacology (Fac. Medicine in Hradec Kralove, Charles Univ.)
  • 2008 – MSc. in Pharmacy (Fac. Medicine in Hradec Kralove, Charles Univ.)

Working Experience

  • since 2017 – Faculty of Pharmacy, Charles Universty, Dpt. Pharmacology and Toxiclogy (Assistant professor)
  • 2008-2017 – Faculty of Medicine in Hradec Králové, Charles Universty, Dpt. Pharmacology (Assistant professor since 2014, Lecturer since 2012, Research assistant since 2008) 

International Experience

  • 2019 (Feb-Sep) - Dr. Gavin Richardson's Lab - Cardiovascular Research Centre, Institute for Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK

Research Interests

  • Cardiotoxicity of antineoplastic agents, environmental pollutants and natural compounds; cardiac regeneration and senescence; pharmacological cardioprotection; DNA topology

Teaching

  • Since 2008 – teaching of seminars and practical classes of Pharmacology I and II in study programme General Medicine (since 2013 also in study programme Dentistry, since 2015 also in English), since 2015 – teaching of lectures of Pharmacology I and II in study programme of General Medicine and Dentistry (Fac. Medicine in Hradec Kralove, Charles Univ.)
  • Since 2017 - teaching of seminars of Pharmacology I and II in study programme Pharmacy (Fac. Pharmacy, Charles Univ.)

Memberships in Scientific Societies

  • Member of European Section of International Society for Heart Research (ISHR)
  • Member of Czech Society for Experimental and Clinical Pharmacology and Toxicology

Memberships in University and Faculty Bodies

  • Member of Academic Senate of Charles University (since 2022)
  • Member of Academic Senate of Faculty of Pharmacy, Charles University (since 2024)

Awards

  • 2015 – EPHAR Poster Award of 65th Pharmacology days; 2013 – Best publication of the year 2012 of young authors (in experimental pharmacology); 2010 – Best Poster Award of 60th Pharmacology days (all awards of the Czech Society for Clinical and Experimental Pharmacology and Toxicology)
  • 2011 – Best Lecture Award (2nd place) at 7th Postgraduate Medical Students Conference (Hradec Kralove)

Grant Projects

  • Principal investigator:
    • Grant Agency of Academy of Science of Czech Repubic (joint Czech-Slovenian project 2024-2026 – “Bisphenol A substitutes: health risks to the endocrine and cardiovascular systems”)
    • Grant Agency of Charles University  (GAUK) (1x)
  • As a co-investigator: Grant Agency of Academy of Science of Czech Republic (GACR) (3x), Charles University Reasearch Centre (UNCE 204019, @CardioToxHK), Charles University Charles University Research Program (PROGRES, PRVOUK, PRIMUS), VZ MSM (1x), IGA MZ (AZV) (3x), GA UK (2x), SVV LFHK (4x).

Publications and Citations:

– Number of publications with IF: 31 - cummualtive IF > 170

– Number of citations without self-citation in WoS/Scopus: 1156/1173. 

– H-index in WoS/Scopus (with self-citations) = 15/16

Summary of all publications:

  1. Mladěnka P, Fadraersada J, Dias P, Tvrdý V, Pourová J, Jirkovský E, Carazo A, Gunaseelan C, Harčárová P, Lomozová Z, Sollner Dolenc M, Trontelj J & Peterlin Mašič L. The first subacute study with oral administration of bisphenol AP in male rats: Cardiovascular data and metabolite detection. Ecotox Environ Safe. 2025; 304: 19143. doi: 10.1016/j.ecoenv.2025.119143.

  2. Hrubša M, Soloviova A, Gunaseelan C, Harčárová P, Lomozová Z, Jirkovský E, Carazo A, Sollner Dolenc M, Peterlin Mašič L & Mladěnka P. A novel bisphenol A alternative, DD-70, may negatively affect haemostasis through cyclooxygenase 1 inhibition. Environ Int. 2025; 203:109738. doi: 10.1016/j.envint.2025.109738.

  3. Alva-Gallegos R, Jirkovský E, Mladěnka P & Carazo A. Small phenolic compounds as potential endocrine disruptors interacting with estrogen receptor alpha. Front Endocrinol. 2024;15:1440654. doi: 10.3389/fendo.2024.1440654

  4. Dias P, Salam R, Pourová J, Vopršalová M, Konečný L, Jirkovský E, Tebbens JD, Mladěnka P. The quercetin metabolite 4-methylcatechol causes vasodilation via voltage-gated potassium (KV) channels. Food Funct. 2024, in press. doi: 10.1039/d3fo04672a

  5. Dias P, Salam R, Moravcová M, Saadat S, Pourová J, Vopršalová M, Jirkovský E, Tebbens JF, Mladěnka P. 3-methoxycatechol causes vasodilation likely via KV channels: Ex vivo, in silico docking and in vivo study. Vasc Pharmacol. 2024; 156: doi: 10.1016/j.vph.2024.107418

  6. Tvrdy V, Dias P, Nejmanova I, Carazo A, Jirkovsky E, Pourova J, Fadraersada J, Moravcova M, Masic LP, Dolenc MS, Mladenka P. The effects of bisphenols on the cardiovascular system ex vivo and in vivo. Chemosphere. 2023 Feb13. doi: 10.1016/j.chemosphere.2022.137565

  7. Moravcova M, Hrubsa M, Lomozova Z, Catapano MC, Argento R, Jirkovsky E, Kucera R, Mercolini L & Mladenka M. A complex methodological approach for the screening of efficient and safe cobalt chelators. Med Chem.  2023;19(5):495-507. doi: 10.2174/1871530322666221006144449

  8. Dias P, Tvrdy V, Jirkovsky E, Dolenc MS, Masic LP, Mladenka P. The effects of bisphenols on the cardiovascular system. Crit Revi Toxicol. 2022;52(1):66-87. doi: 10.1080/10408444.2022.2046690

  9. Pokorna Z, Kollarova-Brazdova P, Lencova-Popelova O, Jirkovsky E, Kubes J, Mazurova Y, Adamcova M, Holeckova M, Palicka V, Simunek T, Sterba M. Primary prevention of chronic anthracycline cardiotoxicity with ACE inhibitor is temporarily effective in rabbits, but benefits wane in post-treatment follow-up. Clin Sci (Lond). 2021;CS20210836. doi: 10.1042/CS20210836

  10. Tvrdy V, Hrubsa M, Jirkovsky E, Biedermann D, Kuty M, Valentova K, Kren V, Mladenka P. Silymarin Dehydroflavonolignans Chelate Zinc and Partially Inhibit Alcohol Dehydrogenase. Nutrients. 2021;13(12):4238. doi: 10.3390/nu13124238

  11. Jirkovsky E, Jirkovska A, Bavlovic-Piskackova H, Skalicka V, Pokorna Z, Karabanovich G, Kollarova-Brazdova P, Kubes J, Lencova-Popelova O, Mazurova Y, Adamcova M, Lyon AR, Roh J, Simunek T, Sterbova-Kovarikova P, Sterba M. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14:e008209. DOI: 10.1161/CIRCHEARTFAILURE.120.008209

  12. Jirkovska A, Karabanovich G, Kubes J, Skalicka V, Melnikova I, Korabecny J, Kucera T, Jirkovsky E, Novakova L, Bavlovic Piskackova H, Skoda J, Sterba M, Austin C, Simunek T, Roh J. Structure-activity relationship study of dexrazoxane analogues reveals ICRF-193 as the most potent bisdioxopiperazine against anthracycline toxicity to cardiomyocytes due to its strong topoisomerase IIβ interactions. J Med Chem. 2021;64(7):3997-4019. doi: 10.1021/acs.jmedchem.0c02157

  13. Dosedel M, Jirkovsky E, Macakova K, Kujovska Krcmova L, Javorska L, Pourova J, Mercolini L, Remiao F, Novakova L, Mladenka P. Vitamin C - Sources, physiological role, kinetics, deficiency, use, toxicity, and determination. Nutrients. 2021;13(2):615. doi: 10.3390/nu13020615

  14. Tvrdy V. Pourova J, Jirkovsky E, Kren V, Valentova K, Mladenka P. Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin. Med Res Rev. 2021;41(4):2195-2246. doi: 10.1002/med.21791

  15. Dookun E, Walaszczyk A, Redgrave R, Palmowski P, Tual‐Chalot S, Suwana A, Chapman J, Jirkovsky E, Donastorg Sosa L, Gill E, Yausep O, Santin Y, Mialet‐Perez J, Owens A, Grieve D, Spyridopoulos I, Taggart M, Arthur H, Passos J, Richardson G. Clearance of senescent cells during cardiac ischemia–reperfusion injury improves recovery. Aging Cell. 2020;e13249. doi: 10.1111/acel.13249

  16. Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Skalická V, Štěrbová-Kovaříková P, Roh J, Šimůnek T, Štěrba M. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity. J Pharmacol Exp Ther. 2020;373(3):402-415. doi: 10.1124/jpet.119.264580

  17. Pokorna Z, Jirkovsky E, Hlavackova M, Jansova H, Jirkovska A, Lencova-Popelova O, Brazdova P, Kubes J, Sotakova-Kasparova D, Mazurova Y, Adamcova M, Vostatkova L, Holzerova K, Kolar F, Simunek T, Sterba M. In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline. Clin Sci (Lond). 2019;133(16):1827-1844. doi: 10.1042/CS20190139

  18. Jirkovsky E, Jirkovska A, Bures J, Chladek J, Lencova O, Stariat J, Pokorna Z, Karabanovich G, Roh J, Brazdova P, Simunek T, Kovarikova P, Sterba M. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart. J Pharmacol Exp Ther. 2018 Mar;364(3):433-446. doi: 10.1124/jpet.117.244848

  19. Lencova-Popelova O, Jansova H, Jirkovsky E, Bures J, Jirkovska-Vavrova A, Mazurova Y, Reimerova P, Vostatkova L, Adamcova M, Hrochf M, Pokorna Z, Kovarikova P, Simunek T and Serba M. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings? Toxicology. 2016;372:52-63. doi: 10.1016/j.tox.2016.11.002

  20. Adamcova M, Popelova-Lencova O, Jirkovsky E, Simko F, Gersl V and Sterba M. Cardiac troponins - Translational biomarkers in cardiology: Theory and practice of cardiac troponin high-sensitivity assays. Biofactors. 2016;42:133-148. doi: 10.1002/biof.1261

  21. Lencova-Popelova O, Jirkovsky E, Jansova H, Jirkovska-Vavrova A, Vostatkova-Tichotova L, Mazurova Y, Adamcova M, Chladek J, Hroch M, Pokorna Z, Gersl V, Simunek T and Sterba M. Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane. J Mol Cell Cardiol. 2016;91:92-103. doi: 10.1016/j.yjmcc.2015.12.021

  22. Adamcova M, Lencova-Popelova O, Jirkovsky E, Mazurova Y, Palicka V, Simko F, Gersl V and Sterba M. Experimental determination of diagnostic window of cardiac troponins in the development of chronic anthracycline cardiotoxicity and estimation of its predictive value. Int J Cardiol. 2015;201:358-367. doi: 10.1016/j.ijcard.2015.07.103

  23. Jirkovska-Vavrova A, Roh J, Lencova-Popelova O, Jirkovsky E, Hruskova K, Potuckova-Mackova E, Jansova H, Haskova P, Martinkova P, Eisner T, Kratochvil M, Sus J, Machacek M, Vostatkova-Tichotova L, Gersl V, Kalinowski D, Muller M, Richardson D, Vavrova K, Sterba M and Simunek T. Synthesis and analysis of novel analogues of dexrazoxane and its open-ring hydrolysis product for protection against anthracycline cardiotoxicity in vitro and in vivo. Toxicol Res. 2015;4:1098-1114. doi: 10.1039/C5TX00048C

  24. Lencova-Popelova O, Jirkovsky E, Mazurova Y, Lenco J, Adamcova M, Simunek T, Gersl V and Sterba M. Molecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up. PLoS One. 2014;9:e96055. doi: 10.1371/journal.pone.0096055

  25. Jirkovsky E, Lencova-Popelova O, Hroch M, Adamcova M, Mazurova Y, Vavrova J, Micuda S, Simunek T, Gersl V and Sterba M. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits. Toxicology. 2013;311:191-204. doi: 10.1016/j.tox.2013.06.012

  26. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V and Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 2013;18:899-929. doi: 10.1089/ars.2012.4795

  27. Jirkovsky E, Popelova O, Krivakova-Stankova P, Vavrova A, Hroch M, Haskova P, Brcakova-Dolezelova E, Micuda S, Adamcova M, Simunek T, Cervinkova Z, Gersl V and Sterba M. Chronic Anthracycline Cardiotoxicity: Molecular and Functional Analysis with Focus on Nuclear Factor Erythroid 2-Related Factor 2 and Mitochondrial Biogenesis Pathways. J Pharmacol Exp Ther. 2012;343:468-478. doi: 10.1124/jpet.112.198358

  28. Vavrova A, Popelova O, Sterba M, Jirkovsky E, Haskova P, Mertlikova-Kaiserova H, Gersl V and Simunek T. In vivo and in vitro assessment of the role of glutathione antioxidant system in anthracycline-induced cardiotoxicity. Arch Toxicol. 2011;85:525-535. doi: 10.1007/s00204-010-0615-8

  29. Sterba M, Popelova O, Lenco J, Fucikova A, Brcakova E, Mazurova Y, Jirkovsky E, Simunek T, Adamcova M, Micuda S, Stulik J and Gersl V. Proteomic insights into chronic anthracycline cardiotoxicity. J Mol Cell Cardiol. 2011;50:849-862. doi: 10.1016/j.yjmcc.2011.01.018

  30. Nachtigal P, Sterba M, Popelova O, Vecerova L, Kudlackova Z, Jirkovsky E and Gersl V. Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery. Histol Histopathol. 2011;26:551-562. doi: 10.14670/HH-26.551

  31. Bendova P, Mackova E, Haskova P, Vavrova A, Jirkovsky E, Sterba M, Popelova O, Kalinowski DS, Kovarikova P, Vavrova K, Richardson DR and Simunek T. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol. 2010;23:1105-14. doi: 10.1021/tx100125t

 

Patent applications

PCT patent applications

  1. WO2021/144746 A1 (PCT/IB2021/050285). Roh J., Štěrba M., Šimůnek T., Štěrbová P., Karabanovich G., Jirkovská A., Jirkovský E., Bavlovič Piskáčková H., Kubeš J., Jansová H., Kollárová P. Use of ICRF-193 derivatives and pharmaceutical preparations containing thereof for the prevention of chronic cumulative cardiotoxicity caused by therapy with anthracycline anticancer drugs. 
© 2026 Charles University, Faculty of Pharmacy in Hradec Králové | Website information | Kentico CMS